Prof. Dr. Alexzander Asea, Chief Executive Officer of the Vaccine Access Initiative (VAI) a subsidiary of Microhaem Scientifics (MHS) was elected to the Board of the African Vaccine Manufacturing Initiative (AVMI), the continent’s principal platform shaping policy, advocacy, and investment alignment for sustainable vaccine manufacturing in Africa.
AVMI operates at the intersection of government policy, regional coordination, development finance, and industrial implementation, addressing systemic barriers to vaccine production including regulatory harmonization, market-shaping mechanisms, technology transfer pathways, and long-term demand certainty. The board-level representation provides a strategic opportunity to influence continental frameworks that directly impact the viability and scale of African biomanufacturing.
Prof. Dr. Asea’s election positions VAI and by extension MHS within the core governance architecture guiding Africa’s vaccine manufacturing agenda, strengthening alignment between on-the-ground manufacturing execution and continental policy formulation. His participation brings practitioner-led insight to AVMI deliberations, grounded in active efforts to establish end-to-end biomanufacturing capacity in Uganda, in compliance with global quality, regulatory, and market access standards.
Commenting on his appointment, Prof. Dr. Asea emphasized that “local vaccine manufacturing is now a strategic imperative for health security, economic resilience, and sovereign capability. and highlighted his commitment to advancing solutions that accelerate technology transfer, strengthen regulatory systems, and enable commercially sustainable African manufacturing enterprises”.
This appointment represents a strategic governance milestone for VAI and MHS, reinforcing their role as credible African manufacturing institutions contributing to the design, not only the delivery, of the continent’s vaccine future. It further signals the increasing influence of African manufacturers in shaping policies, partnerships, and investment decisions critical to long-term continental health security.
